iRadimed (NASDAQ:IRMD) Posts Quarterly Earnings Results, Meets Expectations

iRadimed (NASDAQ:IRMD) issued its quarterly earnings data on Friday. The medical equipment provider reported $0.55 EPS for the quarter, hitting analysts’ consensus estimates of $0.55, FiscalAI reports. iRadimed had a net margin of 26.70% and a return on equity of 23.45%.

Here are the key takeaways from iRadimed’s conference call:

• Record third-quarter results included revenue of $24.2 million, up 14% year over year and 18% sequentially, while GAAP EPS rose to $0.51 from $0.43 a year ago.
• The 3870 MR IV pump launch is gaining traction, with more than 300 systems shipped in Q3, record pump and monitor bookings, and a growing backlog. Management estimates an opportunity of more than 10,000 replacement channels, with the new pump carrying an approximately 23%-25% higher ASP than the older model.
• The company reduced its 2026 revenue outlook to $91.7 million-$93.2 million from $91 million-$96 million and lowered its GAAP EPS range to $1.90-$1.94 from $1.90-$2.05, citing the need to moderate production ramping to protect quality.
• Manufacturing efficiencies lifted gross margin to 76% sequentially, and management expects further improvement in Q4 and potentially a return to 77%-78% or higher in 2027. Management also projected double-digit, potentially upper-teens, revenue growth in 2027 and ended the quarter with $63.3 million in cash while declaring a $0.20 quarterly dividend.

iRadimed Price Performance

IRMD stock traded down $8.96 during midday trading on Friday, hitting $76.78. The company’s stock had a trading volume of 140,509 shares, compared to its average volume of 111,432. The company’s fifty day moving average price is $85.86 and its 200 day moving average price is $92.79. iRadimed has a twelve month low of $76.38 and a twelve month high of $107.90. The stock has a market capitalization of $981.72 million, a P/E ratio of 42.90 and a beta of 0.91.

Wall Street Analyst Weigh In

IRMD has been the subject of a number of research reports. Needham & Company LLC initiated coverage on iRadimed in a report on Tuesday, September 22nd. They set a “hold” rating for the company. Weiss Ratings raised iRadimed from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Friday, October 16th. Finally, Wall Street Zen lowered iRadimed from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $120.00.

Insider Activity at iRadimed

In other news, Director Monty K. Allen sold 1,419 shares of the firm’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $86.41, for a total value of $122,615.79. Following the completion of the transaction, the director owned 19,581 shares in the company, valued at $1,691,994.21. This trade represents a 6.76% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 34.60% of the stock is currently owned by corporate insiders.

About iRadimed

iRadimed Corporation (NASDAQ: IRMD) develops, manufactures and sells medical devices designed for use during magnetic resonance imaging (MRI) procedures. The company focuses on solutions that allow clinicians to deliver intravenous medications and monitor patients safely while they are in or near an MRI scanner.

Its principal products include the MRidium MRI-compatible infusion pump systems, which are designed to administer intravenous fluids and medications without interfering with MRI operations.